SCHEMBL2113434

SCHEMBL2113434

COC(=O)c1cc(OC)c(C)c2c1Oc1c(C=O)c(OC)cc(C)c1C(=O)O2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.58
KMT2A Q03164 9/20 0.58
MAPT P10636 8/20 0.58
ALDH1A1 P00352 8/20 0.58
KDM4E B2RXH2 8/20 0.58
CYP3A4 P08684 8/20 0.58
TDP1 Q9NUW8 7/20 0.58
HPGD P15428 6/20 0.58
THRB P10828 3/20 0.58
RECQL P46063 3/20 0.58
PHPT1 Q9NRX4 2/20 0.58
POLB P06746 2/20 0.58
L3MBTL1 Q9Y468 2/20 0.58
CASP7 P55210 1/20 0.58
CASP6 P55212 1/20 0.58
HSD17B10 Q99714 3/20 0.53
ALOX15 P16050 2/20 0.53
LMNA P02545 2/20 0.53
SLCO1B3 Q9NPD5 3/20 0.42
SLCO1B1 Q9Y6L6 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2111729 0.92 MEN1 (0.58) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL2112603 0.86 TDP1 (0.51) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL2113631 0.83 ALDH1A1 (0.49) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL2114469 0.83 ALDH1A1 (0.48) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL2113411 0.83 KDM4E (0.56) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL2112793 0.82 ALDH1A1 (0.47) MEN1KMT2AMAPTALDH1A1KDM4E
Psoromic Acid SCHEMBL29934794 0.82 MAPT (0.71) MEN1KMT2AMAPTALDH1A1KDM4E
Psoromic Acid SCHEMBL2113679 0.82 MAPT (0.71) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL2113613 0.81 MEN1 (0.55) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL2112898 0.81 MEN1 (0.56) MEN1KMT2AMAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158623-B2 Heptacyclic compounds and the pharmaceutical uses thereof for preventing and treating diabetes and metabolic syndrome SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) 2012-04-17 US disclosed
US-8158623-B2 Heptacyclic compounds and the pharmaceutical uses thereof for preventing and treating diabetes and metabolic syndrome SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) 2012-04-17 US disclosed
US-8158623-B2 Heptacyclic compounds and the pharmaceutical uses thereof for preventing and treating diabetes and metabolic syndrome SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) 2012-04-17 US disclosed
US-20100173905-A1 HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCE 2010-07-08 US disclosed
US-20100173905-A1 HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCE 2010-07-08 US disclosed
US-20100173905-A1 HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCE 2010-07-08 US disclosed
EP-2199295-A1 COMPOUNDS WITH 7-MEMBER CYCLE AND THE PHARMACEUTICAL USE THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLISM SYNDROME Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2010-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173905-A1 HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME GPR119, CYP11B1, HSD11B1 MEN1 730/4885KMT2A 4629/4885MAPT 4246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.